benefit of heated IP perfusion in canines and Palta et al developed an IP therapy filtration system. 4, 5 Historically, the first patient was treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in 1979 for recurrent PMP, having previously undergone CRS. 6 ceal cancer. [10] [11] [12] [13] [14] [15] The benefits of heated IP chemotherapy were also demonstrated in clinical trials by Zimm et al and Howell et al. 7, 8 Currently, CRS and HIPEC have become the standard of care for pseudomyxoma peritonei (PMP) and peritoneal mesothelioma. 16 Conducting clinical trials to validate potential treatment efficacy for PM toward other malignancies has proven difficult. 17, 18 Despite the successes of these previous investigations, there have 
| METHODS
Initially, a PubMed search was conducted using terms "Clinical trial,"
"intraperitoneal chemotherapy," and "HIPEC. 4 | DISCUSSION
| Published clinical studies
Validation of CRS and HIPEC as part of the multimodal disease management system of PM has been hampered by a lack of prospective, clinical trials. To date, a handful of modern published clinical trials exist which address colorectal, appendiceal, ovarian, and gastric cancer with PM, and peritoneal mesothelioma (Table 1 ).
One such trial that made a significant impact in current cancer treatment guidelines is that of Verwaal et al. 20, 21 As a result, the current National Cancer Comprehensive Network (NCCN) Guidelines Median survival in the CRS group was 6.5 months as compared to 11 months in the CRS and HIPEC cohort (P = 0.046). Furthermore, PCI and completeness of cytoreduction (CCR) scores, were both found to have a significant impact on survival. 35 In the 23 patients with a high PCI (≥20), the median overall survival of the CRS and HIPEC group was 13.5 months as compared to 3-month survival in the CRS-only group (P = 0.012). Although a small study cohort, the addition of HIPEC to complete cytoreduction showed improved survival. disease, highlighting the need for effective adjuvant therapy. 44 Spiliotis et al conducted a prospective randomized phase III study investigating the efficacy of HIPEC for epithelial ovarian cancer (EOC). 45 EOC often presents at an advanced stage with spread throughout the abdominopelvic region due to indolent spread. 46 
| Active clinical trials
Despite the successes of previous clinical trials, further studies are required to define the role of CRS and HIPEC in various peritoneal malignancies. Currently, there are a number of clinical trials either actively recruiting or continuing to accrue follow-up data ( Table 2 ).
These studies are being conducted internationally, with over 10 included clinical trials can be found in Table 2 .
| Colorectal/appendiceal
The Because CRS and HIPEC are considered the mainstay of treatment for these types of malignancies, this group is seeking to identify the safer IP chemotherapeutic. 17, 18 The primary outcome measure will be the difference in rate of grade 3 or 4 hematologic toxicities between the two groups, with secondary outcome measures of disease-free survival and quality of life assessments (3 years). As of December 2015 this study has recruited 116 patients. This study may aid in 
| Ovarian
A multi-center, phase II RCT at MSKCC is currently enrolling patients with ovarian, fallopian tube, and primary peritoneal cancers (NCT01767675). This study evolved from an initial small, phase I study demonstrating the safety of CRS and HIPEC in patients with recurrent, platinum-sensitive, epithelial ovarian cancers undergoing secondary cytoreduction. 56 The study will randomize patients to secondary CRS with or without carboplatin-based HIPEC, followed by 
| Gastric
Gastric cancer remains the third leading cause of cancer-related death in China despite improvements in screening and aggressive management. 57 This has led to a number of studies developed in
China to employ HIPEC in managing this disease. Peng et al from the Sixth Affiliated Hospital of Sun Yat-Sen University in China will soon begin a randomized phase III trial to investigate the addition of HIPEC to standard treatment for patients with primary gastric cancer (NCT02960061). All patients will undergo neoadjuvant chemotherapy, followed by gastric resection with D2 lymphadenectomy, and adjuvant chemotherapy. The experimental arm will receive HIPEC, while controls will receive only peritoneal lavage with distilled water.
This group seeks to determine the safety and efficacy of HIPEC prophylactic measure to prevent recurrence due to potential peritoneal seeding at initial resection. 58 Their estimated enrollment of 640 patients will be followed for progression-free survival for patients with gastric PM. 60 Charite University in Germany has began a phase III trial, the GASTRIPEC study, in March 2014. All patients will receive neoadjuvant therapy, followed by CRS, and adjuvant therapy, but patients in the experimental arm will also receive HIPEC. Primary outcome will be overall survival (up to 2.5 years), with secondary measures that include time to progression, quality of life, time to distant metastases, toxicity, and requirement of second surgery. These studies will similarly demonstrate the benefit of HIPEC as a prophylactic measure in patients that may not present with macroscopic PM.
| Pancreatic
Beckert 
| Modifying intraperitoneal drug delivery
Further studies are being conducted internationally that seek to improve the delivery of chemotherapeutics during HIPEC, as well as eliminate remaining disease after maximal cytoreduction. These studies investigate the dosage, temperature, pressure, and timing of intraperitoneal chemotherapy in an effort to define the most effective treatment strategies.
The Fondazione IRCCS Istituto Nazionale dei Tumori (Milan, Italy) is investigating the ability to improve the uptake of chemotherapy by neoplastic tissue after CRS. This will be achieved by using high intra-abdominal pressure (IAP) (18-22 mmHg).
Currently enrolling up to 38 patients, this phase II study will randomize each patient to undergo CRS and HIPEC, with low IAP reporting statistically significant, favorable findings, and therefore more likely to be published, which may introduce bias. The eligibility criteria proposed methodologically herein may limit some of this inherent bias.
Existing evidence to-date should act as a stimulus for conducting appropriate and necessary trials. The ongoing clinical trials discussed here will vary in their impact on the field. Many compare variations of CRS and HIPEC in both control and experimental arms, as it would be potentially unethical to withhold a life-prolonging therapy to one randomized group. This likely introduces a selection bias into a number of these studies, as they will limit the included patients to a subset of patients with PM known to benefit from this treatment strategy. 
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